300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Sweden
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Colombia
China
Armenia
Kuwait
Costa Rica
Czech Republic
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Canada
Germany
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Argentina
Angola
Europe
Cyprus
Spain
Qatar
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Bangladesh
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database

MINTS

VC Fund

Ann Arbor, United States

MINTS is a VC fund in Ann Arbor focused on Health Care and Medical. MINTS initiative is a $25m venture fund for the University of Michigan to leverage commercialization efforts by the Office of Technology Transfer (OTT) for investment purposes while demonstrating support for U-M start-ups. The program will be managed by the University’s Investment office, with the support of OTT and the General Counsel’s Office, aspart of the University’s long-term portfolio of investments.

Total investments:
11
Last investment:
Lead investor:
0%

Last updated:

Industries MINTS invests in

Health CareMedicalSoftwareTherapeuticsBiotechnology

Stages MINTS invests in

Series ASeedSeries BSeries CFunding Round

Countries MINTS invests in

United StatesBelgium

Investment Focus

Industry

  • Health Care 5 (45%)
  • Medical 3 (27%)
  • Software 2 (18%)
  • Therapeutics 2 (18%)
  • Biotechnology 2 (18%)
See all 15 industries →

Stage

  • Series A 3 (27%)
  • Seed 2 (18%)
  • Series B 2 (18%)
  • Series C 1 (9%)
  • Funding Round 1 (9%)
See all 6 stages →

Country

  • United States 5 (45%)
  • Belgium 1 (9%)

Investments

CompanyDescriptionRoundLinks
Confo Therapeutics Confo Therapeutics
Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. $65.2M / Series B / Jul 26, 2024
ONL Therapeutics ONL Therapeutics
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. $15M / Series C / Mar 08, 2023
CubeWorks CubeWorks
CubeWorks’ mission is to accelerate the future of IoT and build a world connected by ubiquitous sensor technology through millimeter-scale smart sensing solutions. In 2013, following a decade of research on ultra-low-power circuitry at the University of Michigan, CubeWorks was founded to advance the next generation of IoT sensors. Today, with thedevelopment of the CubiSens™ Platform, CubeWorks brings to market a portfolio of ultra-small wireless smart sensors. These sensors offer limitless potential across a broad range of applications and provide access to mission-critical information exactly when and where it is needed. $2.4M / Seed / Jun 01, 2022
FlexDex FlexDex
FlexDex is a minimally invasive surgery medical device technology that provides high dexterity. Its platform technology translates the surgeon’s hand, wrist, and arm movements from outside the patient into corresponding movements of an end-effector inside the patient’s body.The company was founded in 2010 and is headquartered in Brighton,Michigan. $13M / Venture - Series Unknown / Aug 24, 2021
ONL Therapeutics ONL Therapeutics
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. $46.9M / Series B / Dec 22, 2020
Ripple Science Ripple Science
Ripple Science delivers web-based software and an active registry that facilitates the recruitment and management of research participants for clinical and translational studies. By adapting sales and marketing automation tools to the process of participant recruitment, Ripple empowers its customers to recruit more participants faster.Thecompany's flagship product, Ripple SaaS, is currently being used by research investigators at more than 75 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia, Cognito Therapeutics, and the University of Michigan. $2.5M / Jan 07, 2020
Ripple Science Ripple Science
Ripple Science delivers web-based software and an active registry that facilitates the recruitment and management of research participants for clinical and translational studies. By adapting sales and marketing automation tools to the process of participant recruitment, Ripple empowers its customers to recruit more participants faster.Thecompany's flagship product, Ripple SaaS, is currently being used by research investigators at more than 75 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia, Cognito Therapeutics, and the University of Michigan. $2.5M / Seed / Jan 07, 2020
Confo Therapeutics Confo Therapeutics
Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. $33.6M / Series A / May 07, 2019
Fifth Eye Fifth Eye
Fifth Eye develops a medical device software that provides a view of a patient’s evolving hemodynamic trajectory. It enables proactive patient care to improve outcomes, avoid adverse events, shorten lengths of stay, and reduce costs. $11.5M / Series A / Apr 01, 2019
Ripple Science Ripple Science
Ripple Science delivers web-based software and an active registry that facilitates the recruitment and management of research participants for clinical and translational studies. By adapting sales and marketing automation tools to the process of participant recruitment, Ripple empowers its customers to recruit more participants faster.Thecompany's flagship product, Ripple SaaS, is currently being used by research investigators at more than 75 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia, Cognito Therapeutics, and the University of Michigan. $1.8M / Seed / Jun 15, 2018
See all 11 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Sweden
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Colombia
China
Armenia
Kuwait
Costa Rica
Czech Republic
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Canada
Germany
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Argentina
Angola
Europe
Cyprus
Spain
Qatar
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Bangladesh
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does MINTS invest in?

MINTS invests primarily in Health Care, Medical and Software startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did MINTS last invest?

The most recent investment recorded for MINTS closed in Jul 2024. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
MINTS Find emails